Modified LCAT Enzymes for HDL Elevation and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular diseases, particularly those related to atherosclerosis, are limited in effectiveness for patients with low HDL cholesterol levels, as statins primarily target high LDL levels, and there is a need for a more efficient method to increase HDL levels and stabilize LCAT proteins for enhanced enzymatic activity and stability.
Innovation Solution
Production of modified LCAT proteins with specific amino acid substitutions and additional modifications, such as immunoglobulin constant regions and water-soluble polymers like polyethylene glycol, to enhance enzymatic activity, stability, and immunogenicity, which are administered to increase HDL levels and treat conditions like atherosclerosis and thrombosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If statins are used to reduce LDL cholesterol levels, then the risk for atherosclerosis is reduced in patients with high LDL levels, but the treatment is ineffective for patients whose primary lipid abnormality is low HDL cholesterol
Solution Approach 1:
The patent modifies the LCAT enzyme by changing amino acid parameters (substitutions at positions 31, 176, and 306) to alter its kinetic properties and stability, enabling it to effectively elevate HDL levels in patients who do not respond to statin therapy. This parameter change approach creates a specialized enzyme variant tailored for low-HDL patients.
Solution Approach 2:
The invention segments the treatment approach by creating distinct therapeutic options: statins for high-LDL patients and modified LCAT enzyme for low-HDL patients. This segmentation allows each treatment to be optimized for its specific target population, improving overall treatment reliability across different patient groups.
2Reliability
If wild-type LCAT protein is administered to increase HDL levels, then reverse cholesterol transport is enhanced, but the protein exhibits limited stability and immunogenicity issues
Solution Approach 1:
The patent applies parameter changes by substituting amino acids at positions 31, 176, and 306 of the LCAT enzyme to enhance its stability and reduce immunogenicity while preserving its ability to elevate HDL levels and promote reverse cholesterol transport.
Solution Approach 2:
The modified LCAT enzyme represents a composite therapeutic agent that combines the native catalytic function of LCAT with engineered stability and reduced immunogenicity features, creating a superior therapeutic protein with multiple optimized properties.
3Productivity
If amino acid substitutions are introduced to enhance LCAT enzymatic activity, then HDL elevation is improved, but the protein structure and function may be compromised
Solution Approach 1:
The patent carefully selects amino acid substitutions at positions 31, 176, and 306 that enhance enzymatic activity and stability without compromising the protein's overall structure and function. These parameter changes are optimized to improve productivity while maintaining reliability.
Solution Approach 2:
The modifications apply local quality changes by introducing specific amino acid substitutions at targeted positions (31, 176, 306) that locally enhance enzymatic activity and stability without affecting the global protein structure, thereby improving productivity while preserving reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified LCAT proteins demonstrate increased enzymatic activity, stability, and ability to elevate HDL levels, providing a more effective treatment for cardiovascular diseases and related disorders by improving the pharmacokinetic properties and reducing immunogenicity compared to wild-type LCAT proteins.
Implementation Method 1
Lecithin-cholesterol acyltransferase (LCAT) is an enzyme which catalyses the esterification of free cholesterol by the transfer of an acyl group from phosphatidylcholine onto 3- hydroxyl group of the cholesterol, forming cholesteryl ester and lysophosphatidylcholine
Data Source
Figure 1
Figure 1
Figure 1
AI summary
The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, coronary heart disease, thrombosis, and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide.